This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heckmann, A. Articles by Sagot, Y. Search for Related Content PubMed PubMed Citation Articles by Heckmann, A. Articles by Sagot, Y.

(American Journal of Pathology. 2004;164:1253-1262.)
© 2004 American Society for Investigative Pathology

IKK2 Inhibitor Alleviates Kidney and Wasting Diseases in a Murine Model of Human AIDS

Angélique Heckmann^*, Caroline Waltzinger^*, Paul Jolicoeur, Michel Dreano, Marie H. Kosco-Vilbois and Yves Sagot^*

From Serono Pharmaceutical Research Institute, ^* Plan-les-Ouates, Switzerland; Laboratory of Molecular Biology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada; Serono International, Plan-Les-Ouates, Switzerland; and NovImmune SA, Geneva, Switzerland

Wasting and renal diseases are frequent complications of HIV (human immunodeficiency virus) infection and are associated with accelerated disease progression and increased mortality. Transgenic mice expressing HIV1 under control of the CD4 promoter develop an AIDS-like disease and were used in the present work to study HIV1-induced wasting and kidney pathology. In this study, we reported that disease evolution paralleled increases in serum urea and creatinine levels, indicating an early and progressive deterioration of kidney function; meanwhile the wasting syndrome characterized by up-regulation of the ubiquitine-proteasome pathway and increased level of serum 3-methyl-histidine levels occurred at later stages just prior to death. Further examination of kidney and muscle pathologies revealed a progressive accumulation of CD45⁺ cells, first affecting the kidneys. In addition, the onset of disease is accompanied by elevated levels of circulating "regulated on activation, normal and secreted T cell expressed and secreted" (RANTES). These results prompted us to assess the effects of AS602868, a specific small molecule inhibitor of IkappaB kinase 2 (IKK2) on disease progression. Inhibition of the NF-B pathway indeed resulted in increased lifespan, kidney and lean body mass preservation. These beneficial results were associated with a reduction of CD45⁺ cells infiltrating the kidneys, amelioration of the renal architecture, and reduced level of circulating RANTES. Together our data provide evidence that IKK2 inhibitors have therapeutic relevance in the treatment of HIV1-associated disorders.

This article has been cited by other articles:

				R. A. Frost and C. H. Lang Regulation of muscle growth by pathogen-associated molecules J Anim Sci, April 1, 2008; 86(14_suppl): E84 - E93. [Abstract] [Full Text] [PDF]

				R. A. Frost and C. H. Lang Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass J Appl Physiol, July 1, 2007; 103(1): 378 - 387. [Abstract] [Full Text] [PDF]

				M. Albaqumi, T. J. Soos, L. Barisoni, and P. J. Nelson Collapsing Glomerulopathy J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2854 - 2863. [Abstract] [Full Text] [PDF]

				S. Martinka and L. A. Bruggeman Persistent NF-{kappa}B activation in renal epithelial cells in a mouse model of HIV-associated nephropathy Am J Physiol Renal Physiol, March 1, 2006; 290(3): F657 - F665. [Abstract] [Full Text] [PDF]

				K. E. Yarasheski, S. R. Smith, and W. G. Powderly Reducing plasma HIV RNA improves muscle amino acid metabolism Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E278 - E284. [Abstract] [Full Text] [PDF]